Zobrazeno 1 - 10
of 399
pro vyhledávání: '"Robert C. Doebele"'
Autor:
David Gonzalez-Martinez, Lee Roth, Thomas R. Mumford, Juan Guan, Anh Le, Robert C. Doebele, Bo Huang, Asmin Tulpule, Magdalena Niewiadomska-Bugaj, Trever G. Bivona, Lukasz J. Bugaj
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract Drug resistance remains a challenge for targeted therapy of cancers driven by EML4-ALK and related fusion oncogenes. EML4-ALK forms cytoplasmic protein condensates, which result from networks of interactions between oncogene and adapter prot
Externí odkaz:
https://doaj.org/article/369d4a9ed829495a9689692c1e1918f3
Publikováno v:
Thoracic Cancer, Vol 14, Iss 33, Pp 3259-3265 (2023)
Abstract Background The vast majority of patients with ROS1 positive non‐small cell lung cancer (NSCLC) derive clinical benefit from currently approved ROS1 therapies, including crizotinib and entrectinib. However, a small proportion of patients tr
Externí odkaz:
https://doaj.org/article/b4a49be5552c4d6ea20d58cdd6f1cf4d
Autor:
Katherine Priest, Anh Le, Amanuail Gebregzabheir, Hala Nijmeh, Gregory B. Reis, Melanie Mandell, Kurtis D. Davies, Carolyn Lawrence, Emily O’Donnell, Robert C. Doebele, Liming Bao, Dara L. Aisner, Erin L. Schenk
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-7 (2023)
Abstract Patients with metastatic NSCLC bearing a ROS1 gene fusion usually experience prolonged disease control with ROS1-targeting tyrosine kinase inhibitors (TKI), but significant clinical heterogeneity exists in part due to the presence of co-occu
Externí odkaz:
https://doaj.org/article/d06abc523d8e46278ad3f301b11a80b8
Autor:
Logan C. Tyler, Anh T. Le, Nan Chen, Hala Nijmeh, Liming Bao, Timothy R. Wilson, David Chen, Brian Simmons, Kristen M. Turner, Dean Perusse, Shailaja Kasibhatla, Jason Christiansen, Arkadiusz Z. Dudek, Robert C. Doebele
Publikováno v:
Thoracic Cancer, Vol 13, Iss 21, Pp 3032-3041 (2022)
Abstract Background ROS1 tyrosine kinase inhibitors (TKIs) have demonstrated significant clinical benefit for ROS1+ NSCLC patients. However, TKI resistance inevitably develops through ROS1 kinase domain (KD) modification or another kinase driving byp
Externí odkaz:
https://doaj.org/article/69b9447303ff45faa281860090224996
Autor:
Laura Schubert, Anh T. Le, Trista K. Hinz, Andre C. Navarro, Sarah K. Nelson-Taylor, Raphael A. Nemenoff, Lynn E. Heasley, Robert C. Doebele
Publikováno v:
Biology Open, Vol 12, Iss 8 (2023)
Externí odkaz:
https://doaj.org/article/b9e7e4875d3e41e1b3b2c29b66661bcb
Autor:
Laura Schubert, Andrew Elliott, Anh T. Le, Adriana Estrada-Bernal, Robert C. Doebele, Emil Lou, Hossein Borghaei, Michael J. Demeure, Razelle Kurzrock, Joshua E. Reuss, Sai-Hong Ignatius Ou, David R. Braxton, Christian A. Thomas, Sourat Darabi, Wolfgang Michael Korn, Wafik S. El-Deiry, Stephen V. Liu
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
PurposeGene fusions involving receptor tyrosine kinases (RTKs) define an important class of genomic alterations with many successful targeted therapies now approved for ALK, ROS1, RET and NTRK gene fusions. Fusions involving the ERBB family of RTKs h
Externí odkaz:
https://doaj.org/article/70a0b6cd821d4f078b9efca4a60b1301
Autor:
Rafal Dziadziuszko, Tiffany Hung, Kun Wang, Voleak Choeurng, Alexander Drilon, Robert C. Doebele, Fabrice Barlesi, Charlie Wu, Lucas Dennis, Joel Skoletsky, Ryan Woodhouse, Meijuan Li, Ching‐Wei Chang, Brian Simmons, Todd Riehl, Timothy R. Wilson
Publikováno v:
Molecular Oncology, Vol 16, Iss 10, Pp 2000-2014 (2022)
Genomic tumour profiling informs targeted treatment options. Entrectinib is a tyrosine kinase inhibitor with efficacy in NTRK fusion‐positive (‐fp) solid tumours and ROS1‐fp non‐small cell lung cancer. FoundationOne® Liquid CDx (F1L CDx), a
Externí odkaz:
https://doaj.org/article/70c5cd67899f40a68e40335c1c0b149a
Autor:
Gaia Bianco, Mairene Coto-Llerena, John Gallon, Venkatesh Kancherla, Stephanie Taha-Mehlitz, Mattia Marinucci, Martina Konantz, Sumana Srivatsa, Hesam Montazeri, Federica Panebianco, Vijaya G. Tirunagaru, Marta De Menna, Viola Paradiso, Caner Ercan, Ahmed Dahmani, Elodie Montaudon, Niko Beerenwinkel, Marianna Kruithof-de Julio, Luigi M. Terracciano, Claudia Lengerke, Rinath M. Jeselsohn, Robert C. Doebele, François-Clément Bidard, Elisabetta Marangoni, Charlotte K. Y. Ng, Salvatore Piscuoglio
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-15 (2022)
GATA3 mutations are common in ER-positive breast cancers yet are not targetable. This study describes pharmacological inhibition of MDM2 as a novel approach to target GATA3 deficiency, providing a molecularly guided treatment for this patient subclas
Externí odkaz:
https://doaj.org/article/9071cb3253ff484fad39debd9d0d2d7d
Autor:
Varsha Ananthapadmanabhan, Thomas C. Frost, Kara M. Soroko, Aine Knott, Brianna J. Magliozzi, Prafulla C. Gokhale, Vijaya G. Tirunagaru, Robert C. Doebele, James A. DeCaprio
Publikováno v:
JCI Insight, Vol 7, Iss 13 (2022)
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine carcinoma of the skin with 2 etiologies. Merkel cell polyomavirus (MCPyV) integration is present in about 80% of all MCC. Virus-positive MCC (MCCP) tumors have few somatic mutations and usua
Externí odkaz:
https://doaj.org/article/48d1999c6108493896009222e6cd2895
Autor:
Alexander Drilon, MD, Chao-Hua Chiu, MD, Yun Fan, MD, Byoung Chul Cho, MD, PhD, Shun Lu, MD, PhD, Myung-Ju Ahn, MD, PhD, Matthew G. Krebs, MD, PhD, Stephen V. Liu, MD, Thomas John, MD, Gregory A. Otterson, MD, Daniel S.W. Tan, MD, Tejas Patil, MD, Rafal Dziadziuszko, MD, PhD, Erminia Massarelli, MD, PhD, Takashi Seto, MD, Robert C. Doebele, MD, PhD, Bethany Pitcher, MSc, Nino Kurtsikidze, MD, Sebastian Heinzmann, PhD, Salvatore Siena, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 6, Pp 100332- (2022)
Introduction: Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion–positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials is presented, with substantially longer fo
Externí odkaz:
https://doaj.org/article/46b674c9f39d4db4b8d61e682c4faee9